Research

A Fulbright award takes clinical pharmacist Jo Hikaka to a prestigious university in the US next year, topping off a full 12 months of awards, fellowships and hefty research grants. She finds time to talk to Anna Lee

Sobering data looking at medicine access and adherence for type 2 diabetes has highlighted the low pick-up rate of vital diabetes drugs by patients of all ethnicities

A new study has highlighted the “clear safety benefit” of pharmacists being included in a patient’s healthcare team – particularly during any transition of care.

A new study supports greater involvement of pharmacists at all points of the patient’s healthcare journey to reduce the severity of medication errors

A common painkiller is sending a steady stream of New Zealand children to the liver transplant waiting list and now a new study is hoped to stem the tide

Douglas Pharmaceuticals is heralding early results of its trial on using ketamine to treat depression as possibly the most significant step in the field for 25 years

The Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated approval pathway

Douglas Pharmaceuticals is heralding early results of its trial on using ketamine to treat depression as possibly the most significant step in the field for 25 years

New Zealand based Douglas Pharmaceuticals Ltd is pleased to announce that a majority of patients with Treatment Resistant Depression experienced rapid relief of their symptoms when treated with R-107 (extended-release oral dose of ketamine) in a Phase 2 study

A study whose lead author is a Te Herenga Waka—Victoria University of Wellington epidemiologist has found the Pfizer-BioNTech COVID-19 vaccine used in New Zealand is not associated with a condition that affects the blood known as idiopathic thrombocytopenic purpura (ITP) and other clotting and bleeding events